AC Immune (ACIU) Accumulated Depreciation (2016 - 2017)
AC Immune (ACIU) posted quarterly Accumulated Depreciation of -$2.7 million for Q3 2017, down 23.22% quarter-over-quarter from -$2.2 million in Q4 2016.
Powered by 
Analysis
AC Immune (ACIU) Accumulated Depreciation (2016 - 2017) Analysis & Trends
AC Immune (ACIU) has reported Accumulated Depreciation for 2 consecutive years, with -$2.7 million the latest figure, recorded in Q3 2017.
- In Q3 2017, Accumulated Depreciation changed N/A year-over-year to -$2.7 million; the TTM figure through Sep 2017 stood at -$2.7 million (changed N/A YoY), while the FY2016 annual figure was -$2.2 million, changed N/A from the prior year.
- Accumulated Depreciation retreated to -$2.7 million in Q3 2017 per ACIU's latest filing, from -$2.2 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at -$2.2 million in Q4 2016 and bottomed at -$2.7 million in Q3 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | AC Immune | 285.13 Mn | 285.13 Mn | - |